Passa al contenuto
Merck
  • Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide.

Eslicarbazepine and the enhancement of slow inactivation of voltage-gated sodium channels: a comparison with carbamazepine, oxcarbazepine and lacosamide.

Neuropharmacology (2014-09-23)
Simon Hebeisen, Nuno Pires, Ana I Loureiro, Maria João Bonifácio, Nuno Palma, Andrew Whyment, David Spanswick, Patrício Soares-da-Silva
ABSTRACT

This study aimed at evaluating the effects of eslicarbazepine, carbamazepine (CBZ), oxcarbazepine (OXC) and lacosamide (LCM) on the fast and slow inactivated states of voltage-gated sodium channels (VGSC). The anti-epileptiform activity was evaluated in mouse isolated hippocampal slices. The anticonvulsant effects were evaluated in MES and the 6-Hz psychomotor tests. The whole-cell patch-clamp technique was used to investigate the effects of eslicarbazepine, CBZ, OXC and LCM on sodium channels endogenously expressed in N1E-115 mouse neuroblastoma cells. CBZ and eslicarbazepine exhibit similar concentration dependent suppression of epileptiform activity in hippocampal slices. In N1E-115 mouse neuroblastoma cells, at a concentration of 250 μM, the voltage dependence of the fast inactivation was not influenced by eslicarbazepine, whereas LCM, CBZ and OXC shifted the V0.5 value (mV) by -4.8, -12.0 and -16.6, respectively. Eslicarbazepine- and LCM-treated fast-inactivated channels recovered similarly to control conditions, whereas CBZ- and OXC-treated channels required longer pulses to recover. CBZ, eslicarbazepine and LCM shifted the voltage dependence of the slow inactivation (V0.5, mV) by -4.6, -31.2 and -53.3, respectively. For eslicarbazepine, LCM, CBZ and OXC, the affinity to the slow inactivated state was 5.9, 10.4, 1.7 and 1.8 times higher than to the channels in the resting state, respectively. In conclusion, eslicarbazepine did not share with CBZ and OXC the ability to alter fast inactivation of VGSC. Both eslicarbazepine and LCM reduce VGSC availability through enhancement of slow inactivation, but LCM demonstrated higher interaction with VGSC in the resting state and with fast inactivation gating.

MATERIALI
Numero di prodotto
Marchio
Descrizione del prodotto

Sigma-Aldrich
Sodio dodecil solfato, BioReagent, suitable for electrophoresis, Molecular Biology, ≥98.5% (GC)
Sigma-Aldrich
Sodio dodecil solfato, ≥99.0% (GC), dust-free pellets
Sigma-Aldrich
Sodio dodecil solfato, ACS reagent, ≥99.0%
Sigma-Aldrich
Sodio dodecil solfato, BioUltra, Molecular Biology, 10% in H2O
Sigma-Aldrich
Sodio dodecil solfato, ReagentPlus®, ≥98.5% (GC)
Sigma-Aldrich
Sodio dodecil solfato, BioUltra, Molecular Biology, ≥99.0% (GC)
Sigma-Aldrich
Sodio dodecil solfato, BioUltra, 20% in H2O
Supelco
Sodio dodecil solfato, dust-free pellets, suitable for electrophoresis, Molecular Biology, ≥99.0% (GC)
Supelco
Sodio dodecil solfato, suitable for ion pair chromatography, LiChropur, ≥99.0%
Sigma-Aldrich
Sodio dodecil solfato, BioXtra, ≥99.0% (GC)
Sigma-Aldrich
Carbamazepine, powder
Sigma-Aldrich
Sodio dodecil solfato, ≥98.0% (GC)
Sigma-Aldrich
Sodio dodecil solfato, 92.5-100.5% based on total alkyl sulfate content basis
Sigma-Aldrich
MES solution, BioUltra, Molecular Biology, 0.5 M in H2O
Sigma-Aldrich
Sodio dodecil solfato, ≥90% ((Assay))
Sigma-Aldrich
Sodio dodecil solfato, tested according to NF, mixture of sodium alkyl sulfates consisting mainly of sodium dodecyl sulfate
Supelco
Carbamazepine, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Carbamazepine, analytical standard
USP
Carbamazepine, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Oxcarbazepine, ≥98% (HPLC), solid
Sodio dodecil solfato, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Carbamazepine, meets USP testing specifications
Sigma-Aldrich
Sodio dodecil solfato, ≥98.0% (GC)
USP
Oxcarbazepine, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Sodio dodecil solfato, BioReagent, Molecular Biology, ≥98.5% (GC), free-flowing, Redi-Dri
Carbamazepine, European Pharmacopoeia (EP) Reference Standard
Oxcarbazepine, European Pharmacopoeia (EP) Reference Standard